Martin P. Bean, owner of a Boca Raton, Florida prescription store, was accused of selling mislabeled oncology drugs to physicians all over the nation, news sources indicate. His firm allegedly marketed the drugs, which he purchased from overseas, as FDA approved even though they were not. Bean, 63, is now faced with multiple charges as part of the alleged scheme, including the sale of unapproved and misbranded drugs, and wire and mail fraud. It is not yet known whether Bean has retained a private criminal defense lawyer.
Reports describe Bean as the operator and owner of GlobalRxStore, a Boca Raton-based pharmaceutical outlet that deals in oncology-related prescriptions, such as Eloxatin, Gemzar, and Zometa. The business has been open for nearly six years, during which time it has sold an untold number of prescription medications to physicians in states all over the country, including Florida, New York, Illinois, and California. Reports also named another business, based out of San Diego, California, called Oberlin Medical Supply and Service Corp., as participating in the scheme. Sources say the California business held a wholesale pharmacy license and would distribute Bean’s prescriptions throughout California.
According to reports, Bean would order generic prescription drugs from other counties, such as India, and rebrand them as US FDA-approved drugs. He allegedly engaged in such activity from February 2005 to late 2011. During that time, reports allege that Bean renamed cheap, generic versions of drugs, such as Zometa and Kytril, and distributed them via his Boca Raton Company, giving them false FDA approved labels. Most of the drugs were designated for cancer patients, sources say. Reports claim that Bean spent $3 million on the overseas prescriptions, transferring a portion of that money to a bank in the United Kingdom.
During one occasion, Bean reportedly ordered a supply of Grandem in 2010. A generic and cheaper version of Kytril, Grandem is not an FDA certified drug. However, Bean allegedly marketed it as Kytril and claimed to his buyer that the drug was FDA-approved.
Reports say that Oberlin Medical, the San Diego-based distributor, handled much of Bean’s distribution tasks in California. When a physician placed an order for one of Bean’s drugs, they would call, fax, or email a Canadian-based order center in Winnipeg, sources purport. Credit card payments were allegedly directed to GlobalRxStore and check were made payable to Oberlin Medical. Buyers would receive statements from Oberlin, reports claim, which made their order appear as though they were “purchased from a licensed wholesale pharmacy in the United States, rather than abroad,” reports indicate.
The operator of the Oberlin Medical Center in California has since pled guilty to charges of shipping and storing mislabeled drugs, sources state. If Bean is convicted as charged, he will have to hand over the assets he acquired from his operation, including several million dollars and a reported 2004 sports car, reports indicate.
A spokesperson from a Florida-certified oncologist board told the press that in some cases, the physicians who purchased drugs from Bean are partially at fault. “These medical oncologists did not do their homework,” he said. “Their patients suffered because they were trying to maintain their profit margin.” It remains unclear whether anyone was injured while taking the mislabeled medications. It is also not yet certain whether any of the physicians accused of buying Bean’s medications will face legal or civil charges.